Doxazosin 8 mg Tablet, 30-count
by Zydus Lifesciences Limited · 30 TABLET in 1 BOTTLE (70771-1115-3)
NDC 70771-1115-03
🏷️ FDA NDC (as labeled)
70771-1115-3
billing pads the package segment with a zero
This package
Contains30-count
Pack sizes4 compare ↓
Also priced by: Part D plans $0.1425/unit — full pricing hub ↓
Rx only
Generic
On market
Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
⚠️
Other active recalls for Doxazosin (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Mar 16, 2023 — CGMP Deviations (Northwind Pharmaceuticals LLC) · FDA recall D-0550-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
🆔 Identity & classification
FDA NDC (as labeled)
70771-1115-3
Product NDC
70771-1115
11-digit billing NDC
70771111503
UNII
86P6PQK0MU
Application #
ANDA208719
SPL Set ID
ac889877-133c-4448-af5a-d77b3cbfe878
Established class (EPC)
alpha-Adrenergic Blocker
Mechanism of action
Adrenergic alpha-Antagonists
DEA schedule
Non-controlled
Marketing category
ANDA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2017-08-31
Route
ORAL
Dosage form
TABLET
Substance
DOXAZOSIN MESYLATE
TE code (Orange Book)
AB · RLD · RS
Why two NDCs?
The FDA registers this code as 70771-1115-3 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1115-03. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️ RxNorm drug class
This medicine belongs to the alpha-Adrenergic Blocker class.
Pharmacologic class
alpha-Adrenergic Blocker
Drug family (ATC)
Alpha-adrenoreceptor antagonists
How it works
Adrenergic alpha-Antagonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
🏭 Manufacturer & labeler
LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA208719 (ANDA)
Labeler code70771
First marketedAug 2017
Product typeHuman Prescription Drug
Portfolio717 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
📖 What it is MedlinePlus · NLM
Doxazosin is used to: treat benign prostatic hyperplasia (BPH; enlarged prostate that can cause difficulty urinating, painful urination or increased urinary frequency or urgency). treat high blood pressure. Doxazosin is in a class of medications called alpha-blockers. It relieves the symptoms of BPH by relaxing the muscles of the bladder and prostate to allow urine to flow more easily. It lowers blood pressure by relaxing the blood vessels so that blood can flow more easily through the body.
Read the full MedlinePlus article ↗📗 Our plain-language guide HelloPharmacist
- Yes, if you're taking the tablet form (like Cardura or generic doxazosin tablets), it can help with both conditions at once. The medication relaxes smooth muscle in the prostate ar...
- Can doxazosin treat both my enlarged prostate and my high blood pressure at the same time?
- That dizziness is a known side effect called postural hypotension — your blood pressure dips when you change positions. It's most common after your first dose or after a dose incre...
- I feel dizzy when I stand up after taking doxazosin. Is that normal, and what should I do?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Doxazosin Mesylate — tap one for details:
1
Nutrient depletion considerations
Doxazosin Mesylate may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about Doxazosin?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
💊 What it looks like
Color
White / Pink / Purple
ShapeRound
Imprint786
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII L06K8R7DQK
A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
-
UNII WZB9127XOA
A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
-
UNII EWQ57Q8I5X
Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII 368GB5141J
A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
-
UNII 5856J3G2A2
A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
7 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.1425 | $4.28 / 30 tablets |
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Doxazosin 8 mg 00093-2067-01 | Teva | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 00832-1359-11 | Upsher-Smith | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 16571-0168-01 | Rising | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 23155-0095-01 | Heritage | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin Mesylate 8 mg 29300-0354-01 | Unichem | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 50268-0225-15 | AvPAK | 50 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 59651-0895-01 | Aurobindo | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 59762-2480-07 | Mylan | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 60505-0096-00 | Apotex | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin mesylate 8 mg 62135-0054-90 | Chartwell | 90 tablets | $0.100 | — | Availability likely | — |
| Doxazosin 8 mg 68382-0786-01 | Zydus | 100 tablets | $0.100 | AB | Availability likely | — |
| Doxazosin 8 mg 16729-0415-01 | Accord | 100 tablets | $0.106 | AB | Availability likely | — |
| Cardura 8 mg 00049-2716-10 | ROERIG | 100 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 42291-0260-01 | AvKARE | 100 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 50090-3143-00 | A-S | 30 tablets | — | AB | FDA listed | — |
| Cardura 8 mg 58151-0077-01 | Viatris | 100 tablets | — | AB | FDA listed | — |
| Doxazosin mesylate 8 mg 59762-1391-07 | Mylan | 100 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mgthis 70771-1115-03 | Zydus | 30 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 71610-0160-16 | Aphena | 6000 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 71610-0628-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 71610-0831-53 | Aphena | 60 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 71610-0878-60 | Aphena | 90 tablets | — | AB | FDA listed | — |
| Doxazosin 8 mg 84677-0047-01 | Golden | 100 tablets | — | AB | FDA listed | — |
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2017
On the market since
Aug 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Doxazosin — the ingredient across all brands.
Top reported reactions
Reporter sex
Male · 66%
Female · 34%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 70771-1115-00 | 1000 TABLET in 1 BOTTLE (70771-1115-0) | 2017-08-31 | Active |
| 70771-1115-01 | 100 TABLET in 1 BOTTLE (70771-1115-1) | 2017-08-31 | Active |
| 70771-1115-03 You're viewing this | 30 TABLET in 1 BOTTLE (70771-1115-3) | 2017-08-31 | Active |
| 70771-1115-04 | 10 BLISTER PACK in 1 CARTON (70771-1115-4) / 10 TABLET in 1 BLISTER PACK (70771-1115-2) | 2017-08-31 | Active |
Pack size FAQ
What quantity is in NDC 70771-1115-03?
NDC 70771-1115-03 is a 30-count package — 30 tablet in 1 bottle.
What is the difference between NDC 70771-1115-03 and NDC 70771-1115-01?
Both are Doxazosin 8 mg Tablet — the drug itself is identical. NDC 70771-1115-03 is the 30-count package, while NDC 70771-1115-01 is the 100 tablets package.
What NDC number is used to bill for this package of Doxazosin 8 mg Tablet?
Bill NDC 70771-1115-03 — the 11-digit billing format is 70771111503. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.
🧭 About this NDC listing & data coverage
Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 70771-1115-3, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 70771-1115-03, written without dashes as 70771111503. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 70771-1115-03, the first segment (70771) is the labeler code FDA assigned to Zydus Lifesciences Limited; the middle segment (1115) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (03) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 3 other package presentations of this same product, including 100 tablets (70771-1115-01), 100 tablets (70771-1115-04), 1000 tablets (70771-1115-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No readable label sections were found for this product.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.